I've listened to theZenith AGM several times and given your point of the discovery of how zen3694 modulated the impact of enzalutimide on PSA with varying levels of each drug in that single patient I wondered why during the question period said he wants CURATE.AI to pay to replicate this approach on other patients. Obviously there could be many reasons such as limited $ as the most obvious. However, if this was replicated in some of those patients that still have forward arrows in the beautiful graph it would seem to become much more convincing to suitors.

Perhaps the teaser campaign that Don started with GAC at the R & R and fostered at the AGM is actually much further along. I hope it is and that Don did not feed us another tactic like the "many ROIs on RVX".

Time will tell but the exciting news continues to flow on the science side.

GLTA

Toinv